Pharmaceuticals, Biotechnology & Life Sciences

Azitra Inc’s insider buying spree signals executive confidence in its dermatology‑engineered protein pipeline, but investors must watch clinical milestones and funding to validate the upside.

Quantum‑Si’s CFO sell‑to‑cover trade shows disciplined insider activity amid a strategic pivot into renewable‑energy partnerships and value‑based reimbursement, suggesting a stable foundation for biotech investors.

Insider buying fuels confidence in Amarin’s growth, with senior leadership adding ADS and RSUs amid a robust cardiovascular pipeline—what this means for investors.

Explore how Bicara Therapeutics’ insider trades, Phase III progress, and strategic pricing reveal a disciplined plan for growth in the specialty‑biologic market.

Insider buying at Eton Pharmaceuticals signals confidence in its low‑priced, high‑potential pipeline, offering investors a contrarian entry point amid a 12‑week decline.

Opus Genetics insider confidence rises with a 24,367‑unit RSU grant, boosting leadership stakes and fueling a 19.17% monthly rally, hinting at future growth.

United Therapeutics insider trades reveal CEO confidence in a growing pulmonary hypertension pipeline and a disciplined, long‑term capital strategy.

Prelude Therapeutics’ latest warrant deal with Baker Bros. offers zero‑cost equity access while keeping dilution low, giving investors a unique view of future capital flexibility and pipeline impact.

Belite Bio’s insider sales and Tinlarebant’s Breakthrough therapy status: a balanced view of liquidity moves, commercial strategy, and investor outlook.

CareDx CFO/COO buys 24,134 restricted shares, boosting his stake as the company’s stock surges 17%—a bullish insider move amid new AlloSeq Nano platform growth.